NCT06628128View on ClinicalTrials.gov

A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With Phenylketonuria

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

February 29, 2028

Conditions
Phenylketonuria (PKU)
Interventions
DRUG

JNT-517 Tablet

JNT-517: 75 mg BID

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY